文章：

靶向MET扩增：治疗策略中的机遇与挑战

TargetingMETAmplification: Opportunities and Obstacles in Therapeutic Approaches

原文发布日期：14 September 2023

DOI: 10.3390/cancers15184552

类型: Article

开放获取: 是

英文摘要：

TheMETgene plays a vital role in cellular proliferation, earning it recognition as a principal oncogene. Therapies that targetMETamplification have demonstrated promising results both in preclinical models and in specific clinical cases. A significant obstacle to these therapies is the ability to distinguish between focal amplification and polysomy, a task for which simpleMETcopy number measurement proves insufficient. To effectively differentiate between the two, it is crucial to utilize comparative measures, including in situ hybridization (ISH) with the centromere or next generation sequencing (NGS) with adjacent genes. Despite the promising potential ofMETamplification treatment, the judicious selection of patients is paramount to maximize therapeutic efficacy. The effectiveness of MET inhibitors can fluctuate depending on the extent ofMETamplification. Future research must seek to establish the ideal threshold value forMETamplification, identify the most efficacious combination therapies, and innovate new targeted treatments for patients exhibitingMETamplification.

摘要翻译： 

MET基因在细胞增殖中扮演着关键角色，被确认为主要致癌基因。针对MET扩增的疗法在临床前模型及特定临床案例中已展现出良好疗效。当前治疗面临的主要挑战在于区分局部扩增与多体性，而单纯的MET拷贝数测量无法满足这一鉴别需求。为有效区分两者，必须采用包括着丝粒原位杂交（ISH）或邻近基因二代测序（NGS）在内的对比检测方法。尽管MET扩增治疗前景广阔，但合理筛选患者对实现最佳疗效至关重要。MET抑制剂的疗效会随MET扩增程度而波动。未来研究需致力于确立MET扩增的理想阈值，探索最有效的联合治疗方案，并为存在MET扩增的患者开发新型靶向疗法。

原文链接：

TargetingMETAmplification: Opportunities and Obstacles in Therapeutic Approaches